Kilitch Drugs (India) Limited AI Stock Analysis
Want to see IN:KILITCH full AI Analyst Report?
Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis
Kilitch Drugs (India) Limited
(NSE:KILITCH)
The score is primarily constrained by weak cash generation—free cash flow has been persistently negative and deteriorated sharply in 2026, raising funding risk despite revenue growth and decent accounting profitability. Technicals are mixed with weak near-term momentum, while valuation appears mid-range based on the P/E provided.
Kilitch Drugs (India) Limited (KILITCH) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 7.52B
- Dividend Yield
- ―
- Average Volume (3M)
- 6,370
- Price to Earnings (P/E)
- 30.9
- Beta (1Y)
- 0.63
- Revenue Growth
- 13.87%
- EPS Growth
- -17.80%
- Country
- India
- Employees
- 236
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Kilitch Drugs (India) Limited Business Overview & Revenue Model
Company Description
Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for expor...
How the Company Makes Money
Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical finished dosage formulations (i.e., manufactured drug products) to customers in India and in international markets. Its revenue model is centered on: (1) Branded and/or gen...
Kilitch Drugs (India) Limited Financial Statement Overview
Summary
Strong multi-year revenue growth and improved profitability support the score, and leverage remains manageable. However, persistently negative free cash flow (sharply worse in 2026) and weaker cash conversion versus earnings, alongside rising debt, materially increase funding risk and pull the score down.
Income Statement
74PositiveBalance Sheet
71PositiveCash Flow
38Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.39B | 2.35B | 1.98B | 1.54B | 1.40B | 1.14B |
| Gross Profit | 927.81M | 914.13M | 937.39M | 731.38M | 624.64M | 337.44M |
| EBITDA | 384.05M | 478.38M | 426.26M | 287.43M | 206.50M | 134.13M |
| Net Income | 240.91M | 301.66M | 267.01M | 146.01M | 104.48M | 73.67M |
Balance Sheet | ||||||
| Total Assets | 4.64B | 4.58B | 3.13B | 2.40B | 2.20B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 577.35M | 687.39M | 593.98M | 690.19M | 591.77M | 572.43M |
| Total Debt | 966.43M | 887.09M | 494.24M | 316.46M | 221.94M | 204.32M |
| Total Liabilities | 1.80B | 1.81B | 1.12B | 643.88M | 689.41M | 695.55M |
| Stockholders Equity | 2.89B | 2.80B | 2.02B | 1.76B | 1.52B | 1.39B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -805.64M | -293.31M | -65.97M | -12.26M | -24.19M |
| Operating Cash Flow | 0 | 189.43M | 175.42M | -1.46M | 25.86M | 57.83M |
| Investing Cash Flow | 0 | -1.01B | -399.47M | -95.45M | 79.15M | -152.50M |
| Financing Cash Flow | 0 | 880.13M | 132.43M | 88.07M | -7.16M | 70.28M |
Kilitch Drugs (India) Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Positive. The current price of 215.40 is above the 20-day moving average (MA) of 208.10, above the 50-day MA of 208.82, and above the 200-day MA of 178.51, indicating a bullish trend. The MACD of -2.97 indicates Positive momentum. The RSI at 53.89 is Neutral, neither overbought nor oversold. The STOCH value of 55.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KILITCH.
Kilitch Drugs (India) Limited Peers Comparison
Overall Rating
IN:ZIMLAB60Neutral
IN:KILITCH57Neutral
IN:ALBERTDAVD54Neutral
IN:VALIANTLAB48.6Neutral
IN:MEDICAMEQ48Neutral
IN:NECLIFE47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | INR 7.60B | 263.30 | ― | ― | 13.14% | -60.77% | |
| 57Neutral | INR 7.53B | 30.88 | ― | ― | 13.87% | -17.80% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 4.48B | 15.52 | ― | 0.63% | 19.69% | ― | |
| 49Neutral | INR 5.72B | 35.15 | ― | ― | 102.37% | 176.45% | |
| 48Neutral | INR 3.83B | 35.44 | ― | 0.36% | 27.47% | 6.56% | |
| 47Neutral | INR 2.08B | -0.93 | ― | ― | -99.85% | 78.93% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:KILITCH | Kilitch Drugs (India) Limited | 215.40 | 36.05 | 20.10% | |
| IN:ALBERTDAVD | Albert David Ltd | 785.00 | -21.09 | -2.62% | |
| IN:MEDICAMEQ | Medicamen Biotech Limited | 282.70 | -113.26 | -28.60% | |
| IN:NECLIFE | Nectar Lifesciences Ltd. | 10.73 | -3.91 | -26.71% | |
| IN:VALIANTLAB | Valiant Laboratories Ltd. | 105.35 | 25.54 | 32.00% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 141.70 | 68.74 | 94.22% |
Kilitch Drugs (India) Limited Corporate Events
Kilitch Drugs conducts fully virtual 34th AGM, highlights performance and governance
Kilitch Drugs (India) Limited held its 34th Annual General Meeting on August 27, 2026, conducted entirely via video conferencing in line with Companies Act and regulatory guidelines. The virtual AGM, attended by the full board, key management, statut...
Kilitch Drugs Files SEBI-Compliant Monitoring Report for June Quarter
Kilitch Drugs (India) Limited has submitted a monitoring agency report for the quarter ended June 30, 2026 to BSE and NSE, in line with disclosure requirements under SEBI’s listing and capital issue regulations. The report, prepared by Infomerics Val...
Kilitch Drugs Publishes Quarterly Results in Marathi and English Dailies
Kilitch Drugs (India) Limited has reported that extracts of its financial results for the quarter ended 30 June 2026 have been published in both Marathi and English newspapers. The publication, dated 15 August 2026, fulfills the company’s regulatory...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026
